Macmillan invests in Lucida Medical’s AI prostate most cancers diagnostic support – TechToday

Advertisement: Click here to learn how to Generate Art From Text

Macmillan Most cancers Assist is investing £350,100 in Lucida Medical’s new AI platform, Pi, with the goal of enhancing the pace and accuracy of prostate most cancers assessments.

This might assist to enhance early detection and therapy and cut back the variety of cancer-free sufferers going by way of extra invasive investigative procedures, in addition to probably saving NHS money and time. 

Prostate most cancers is the commonest most cancers in UK males. There are greater than 500,000 males dwelling with prostate most cancers throughout the UK and over 50,000 are identified every year. These numbers are rising and Macmillan estimates that by 2040 there will likely be 1 million males dwelling with prostate most cancers within the UK. It’s a standard false impression that prostate most cancers is innocent: whereas the bottom grades of prostate most cancers develop slowly, 12,000 males die from it every year within the UK.

Pi is constructed utilizing Lucida Medical’s AI coaching know-how that that has been skilled to determine prostate most cancers from MRI scans. Preliminary evaluation suggests the software program has accuracy corresponding to skilled radiologists, based on outcomes introduced on the 2023 Worldwide Most cancers Imaging Society annual assembly from a various group of six NHS hospitals who’re taking part within the PAIR-1 medical research. Making the Pi software program accessible to radiologists throughout the NHS might assist pace up the work of radiologists and cut back the chance of each lacking cancers and pointless biopsies.

Prof Evis Sala, chief medical officer and co-founder of Lucida Medical, stated: “We seek to give every radiologist technology that can precisely identify significant cancers, allowing more patients to benefit from early detection and treatment. At the same time, the accuracy of Pi could help reduce the numbers of prostate cancer-free men who undergo painful, potentially avoidable investigations, saving the NHS costs, helping address the shortage of radiologists, and cutting waiting lists.”

Dr Antony Rix, CEO of Lucida Medical, added: “We are delighted to work with Macmillan, as a leading cancer charity who share our vision for Pi to transform the prospects of patients using AI. Prostate cancer is the most common cancer in males and numbers are projected to rise 62% by 2040. Prostate cancer screening is associated with earlier stages of detection and better survival rates. Avoiding unnecessary biopsies can have a transformative impact on the NHS as well as on patients.” 

Tanya Humphreys, director of innovation at Macmillan, commented: “Lucida Medical’s AI platform has the potential to transform the diagnosis of prostate cancer. Integrating AI with MRI analysis, Pi™ offers a level of precision in diagnosis that could greatly enhance the accuracy and efficiency of prostate cancer detection. Our consultations with leading clinicians, people with cancer, and health technology experts have all attested to the likely impact of Lucida’s technology in reducing the rate of missed cancers and unnecessary biopsies, thereby improving patient outcomes and experience. We are really excited about the possibilities this partnership brings and are deeply committed to advancing cancer care in the UK.” 

The funding in Lucida Medical is Macmillan Most cancers Assist’s second from its Innovation Impression Funding Portfolio. Over the following two years, the brand new portfolio will likely be investing £3.5 million in start-up companies which are creating revolutionary most cancers care merchandise and know-how. Macmillan’s help Lucida Medical in various methods, together with aiding the event of Pi with its Innovation Neighborhood, made up of individuals dwelling with most cancers. 

Lucida Medical will reveal Pi on the 2024 European Congress of Radiology, the place Dr Rix will current the outcomes of the newest analysis on the Pi platform. Pi is out there to be used within the UK and EU to help the prognosis of prostate most cancers.

‘ Credit score:
Unique content material by – “Macmillan invests in Lucida Medical’s AI prostate most cancers diagnostic support – TechToday”

Learn the total article at

Leave a Reply

Your email address will not be published. Required fields are marked *